The use of glucocorticoids, at doses prescribed by rheumatologists, for inflammatory arthritis resulting from checkpoint inhibitors may not substantially impact cancer outcomes, according to data presented at ACR Convergence 2025.

“Glucocorticoids are a cornerstone of treatment for many cases of immune checkpoint inhibitor inflammatory arthritis (ICI-IA),” Deanna Jannat-Khah, MPH, DrPH, assistant scientist at HSS explained. “However, there is no standardized dose, taper regimen or duration for glucocorticoid treatment.

Read the full article at healio.com.